Evidence map›Paper›PMID 30547045›Full record

ArticleJournal of biological methods2018

Patient-derived xenograft model for uterine leiomyoma by sub-renal capsule grafting.

Vanida Ann Serna, Takeshi Kurita

Open access · diamondAbstract read
In one paragraph

Article in Journal of biological methods, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Cellular kinetics ofEndocrine-related cancer · 2018
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Vanida Ann SernaDepartment of Cancer Biology and Genetics, The Comprehensive Cancer Center, Ohio State University, Columbus, OH, USA.
Takeshi KuritaDepartment of Cancer Biology and Genetics, The Comprehensive Cancer Center, Ohio State University, Columbus, OH, USA.
The Ohio State University · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI WANCAI YANG · 1985 to 2026
$132.3M
Xenograft Study on Growth-Control of Human Uterine LeiomyomataR01HD064402 · NICHD · OHIO STATE UNIVERSITY · PI KURITA, TAKESHI · 2010 to 2014
$1.6M
Molecular Etiology of Cervicovaginal Adenosis by in Utero Hormone ExposureR01CA154358 · NCI · OHIO STATE UNIVERSITY · PI KURITA, TAKESHI · 2010 to 2014
$1.5M
NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA154358NICHD NIH HHS R01 HD064402
6 · The paper itself

Abstract

Uterine leiomyoma (UL) or fibroid is a benign smooth muscle tumor of the myometrium with a lifetime incidence of approximately 70%. ULs often require medical intervention due to severe symptoms such as heavy menstrual bleeding and abdominal pain. Although the most common and effective management of ULs is surgical removal, the invasive surgical procedure imposes physical and psychological burdens on the patients. Moreover, the economic burden of UL on health care system is enormous due to the high cost of surgeries. Thus, therapeutic options with long-term efficacy to replace surgical management are urgently needed. For the development of such medical options, reliable preclinical research models are imperative.

Indexed as

estradiolfibroidsmyometriumNSG mousepatient-derived xenograftpreclinical modelprogesterone

Identifiers

PMID30547045
PMCPMC6289531
OpenAlexW2799781484

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.